Search for tag: "nsclc"

02:31 Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark… Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark Socinski	Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark Socinski IMpower110 是第一個 PD-L1 藥物 (Tecentriq) 被證實在第一線單獨使用相對於化療能夠大幅提高病患整體存活期 (20.2 mo vs 13.1 mo)。可以提供無法接受化療或是無法申請到健保的病患一個有效的治療選擇。 tecentriq nsclc impower110 From Yi Chang on March 25th, 2021 0 likes 17 plays 0 Content Declaration Keep for 3 Years COREMAP Content classification C4 No. Language (In English) Chinese, English
02:31 Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark… Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark Socinski	Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark Socinski IMpower110 是第一個 PD-L1 藥物 (Tecentriq) 被證實在第一線單獨使用相對於化療能夠大幅提高病患整體存活期 (20.2 mo vs 13.1 mo)。可以提供無法接受化療或是無法申請到健保的病患一個有效的治療選擇。 tecentr nsclc impower110 From Yi Chang on March 23rd, 2021 0 likes 11 plays 0 Content Declaration Keep for 3 Years COREMAP Content classification C4 No. Language (In English) Chinese, English
01:25:46 Transforming the treatment of patients with… Transforming the treatment of patients with advanced ALK+ NSCLC	Transforming the treatment of patients with advanced ALK+ NSCLC Zoom Recording ID: 95846265211 UUID: dzXQD7usSyWLnh0/6HF0+w== Meeting Time: 2021-03-19T09:28:36Z #webinar #alk #nsclc #mdt #collaboration From Mohammad Shafiqul Haque on March 19th, 2021 0 likes 15 plays Content Declaration Keep for 3 Years COREMAP Content classification C4 No. Language (In English) English
15:53 Down the Ocular Episode # 3 - VENTANA PD-L1… Down the Ocular Episode # 3 - VENTANA PD-L1 (SP142) Assay in NSCLC Part 2	Down the Ocular Episode # 3 - VENTANA PD-L1 (SP142) Assay in NSCLC Part 2 This episode is part 2 in a series on the PD-L1 (SP142) assay in non small cell lung cancer. In this episode, Roche Tissue Diagnostics Medical and Scientific Affairs colleagues Bharathi Vennapusa, MD… sp142 nsclc From Bharathi Vennapusa on November 20th, 2020 0 likes 2 plays Content Declaration Keep for 3 Years Language (In English) English
13:00 Down the Ocular Episode # 2 - VENTANA PD-L1… Down the Ocular Episode # 2 - VENTANA PD-L1 (SP142) Assay in NSCLC Part 1	Down the Ocular Episode # 2 - VENTANA PD-L1 (SP142) Assay in NSCLC Part 1 In this episode, Roche Tissue Diagnostics Medical and Scientific Affairs colleagues Bharathi Vennapusa, MD and Tabari Baker, PhD discuss the PD-L1 (SP142) assay in non-small cell lung cancer. Drs.… sp142 nsclc From Bharathi Vennapusa on November 20th, 2020 0 likes 5 plays Content Declaration Keep for 3 Years Language (In English) English
01:16:25 Setting The Standards for 1st Line ALK NSCLC… Setting The Standards for 1st Line ALK NSCLC Treatment	Setting The Standards for 1st Line ALK NSCLC Treatment Interactive case-study focused webinar to learn about:• Differences in survival, CNS control and toxicity profiles among current andemerging treatment specifically in the landscape of 1L ALK+… alecensa tanujaa muhammad azrif riyaz shah alexander drilon alectinib nsclc From Kelda Tan on September 28th, 2020 0 likes 58 plays 0 Content Declaration Keep for 3 Years Language (In English) English
02:09:00 Global Vision: Immunotherapy in NSCLC (26May2020) Global Vision: Immunotherapy in NSCLC (26May2020)	Global Vision: Immunotherapy in NSCLC (26May2020) Prof Zhou Caicun (Shanghai Pulmonary Hospital, Tongji University School of Medicine Shanghai), Dr Ross Soo (National University Cancer Institute, Singapore) and a panel of Chinese oncologists were… tecentriq lung nsclc impower150 impower110 zhou caicun ross soo From Kelda Tan on June 1st, 2020 0 likes 25 plays 0 Content Declaration Keep for 3 Years Language (In English) English